Icu Medical Inc. Insider Trading

ICUI

Last 12 months

Insiders sold $8.27M and bought nothing on the open market.

43% of the selling was scheduled in advance under 10b5-1 plans. Chief Operating Officer Christian B. Voigtlander sold $1.63M on Aug 11, 19% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2025.

Net open-market

−$8.27M

0 buys · 13 sales

Under a 10b5-1 plan

43%

of the value sold

Insiders who bought / sold

0 / 7

executives and directors

Last open-market buy

Aug 2025

Aug 27, 2025

Get an email when ICUI's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 3	Virginia Ruth Sanzone VP, General Counsel	Sold10b5-1 plan 4 parts	4,856	$168.69 average	819K	25%	Form 4
Sep 1	Brian Michael Bonnell Chief Financial Officer	Sold10b5-1 plan	6,381	$175.00	$1.12M	10%	Form 4
Aug 31	Brian Michael Bonnell Chief Financial Officer	Sold10b5-1 plan 4 parts	9,307	$172.79 average	$1.61M	13%	Form 4
Aug 13	Daniel Woolson VP, GM-Infusion Capital	SoldNo plan	5,417	$181.33	982K	24%	Form 4
Aug 12	Ben Sousa Chief Information Officer	SoldNo plan	2,250	$178.32	401K	42%	Form 4
Aug 11	Christian B. Voigtlander Chief Operating Officer	SoldNo plan	8,929	$182.93	$1.63M	19%	Form 4
Aug 11	Elisha W Finney Director	SoldNo plan	378	$182.48	69K	7.2%	Form 4
May 22	Daniel Woolson President	SoldNo plan	2,123	$132.21	281K	8.6%	Form 4
May 14	Virginia Ruth Sanzone VP, General Counsel	SoldNo plan	2,447	$124.08	304K	11%	Form 4
May 12	David C. Greenberg Director	SoldNo plan	2,424	$122.91	298K	21%	Form 4
Nov 25, 2025	Daniel Woolson VP, GM-Infusion Capital	SoldNo plan	2,897	$152.35	441K	20%	Form 4
Nov 11, 2025	Virginia Ruth Sanzone VP, General Counsel	SoldNo plan	930	$142.35	132K	15%	Form 4
Nov 11, 2025	Elisha W Finney Director	SoldNo plan	1,285	$140.42	180K	24%	Form 4
Aug 27, 2025	David C. Greenberg Director	Bought 2 parts	1,200	$126.41 average	152K	17%	Form 4
Aug 14, 2025	Vivek Jain Chairman and CEO	Bought 2 parts	21,929	$112.83 average	$2.47M	11%	Form 4
May 30, 2025	Virginia Ruth Sanzone VP, General Counsel	SoldNo plan	700	$133.62	94K	9.9%	Form 4
May 27, 2025 – May 28, 2025	Christian B. Voigtlander Chief Operating Officer	SoldNo plan 2 parts	9,930	$129.74 average	$1.29M	62%	Form 4
May 22, 2025 – May 23, 2025	Christian B. Voigtlander Chief Operating Officer	SoldNo plan 2 parts	9,918	$130.02 average	$1.29M	67%	Form 4
May 20, 2025 – May 21, 2025	Christian B. Voigtlander Chief Operating Officer	SoldNo plan 2 parts	9,788	$135.05 average	$1.32M	73%	Form 4
May 19, 2025	Elisha W Finney Director	SoldNo plan	600	$138.92	83K	16%	Form 4
May 16, 2025 – May 19, 2025	Christian B. Voigtlander Chief Operating Officer	SoldNo plan 2 parts	11,110	$139.00 average	$1.54M	82%	Form 4
May 15, 2025	Ben Sousa Chief Information Officer	SoldNo plan	2,000	$137.36	275K	81%	Form 4
May 14, 2025 – May 15, 2025	Christian B. Voigtlander Chief Operating Officer	SoldNo plan 2 parts	11,111	$137.10 average	$1.52M	82%	Form 4
May 13, 2025	David C. Greenberg Director	SoldNo plan	1,942	$143.66	279K	21%	Form 4
Jan 2, 2025	Vivek Jain Chairman and CEO	Sold10b5-1 plan	1,373	$155.48	213K	0.7%	Form 4
Dec 6, 2024	Daniel Woolson VP, GM-Infusion Capital	SoldNo plan	2,241	$156.25	350K	17%	Form 4
Dec 2, 2024	Vivek Jain Chairman and CEO	Sold10b5-1 plan 3 parts	12,000	$162.91 average	$1.95M	5.8%	Form 4
Nov 27, 2024	Christian B. Voigtlander Chief Operating Officer	SoldNo plan	1,430	$158.00	226K	100%	Form 4
Nov 27, 2024	David C. Greenberg Director	SoldNo plan	972	$158.11	154K	15%	Form 4
Nov 25, 2024 – Nov 26, 2024	Christian B. Voigtlander Chief Operating Officer	SoldNo plan 3 parts	9,681	$161.14 average	$1.56M	100%	Form 4

Sep 310b5-1 plan
Virginia Ruth Sanzone
VP, General Counsel · sold 4,856 at avg $168.69
819K
25% of stake
Sep 110b5-1 plan
Brian Michael Bonnell
Chief Financial Officer · sold 6,381 at $175.00
$1.12M
10% of stake
Aug 3110b5-1 plan
Brian Michael Bonnell
Chief Financial Officer · sold 9,307 at avg $172.79
$1.61M
13% of stake
Aug 13No plan
Daniel Woolson
VP, GM-Infusion Capital · sold 5,417 at $181.33
982K
24% of stake
Aug 12No plan
Ben Sousa
Chief Information Officer · sold 2,250 at $178.32
401K
42% of stake
Aug 11No plan
Christian B. Voigtlander
Chief Operating Officer · sold 8,929 at $182.93
$1.63M
19% of stake
Aug 11No plan
Elisha W Finney
Director · sold 378 at $182.48
69K
7.2% of stake
May 22No plan
Daniel Woolson
President · sold 2,123 at $132.21
281K
8.6% of stake
May 14No plan
Virginia Ruth Sanzone
VP, General Counsel · sold 2,447 at $124.08
304K
11% of stake
May 12No plan
David C. Greenberg
Director · sold 2,424 at $122.91
298K
21% of stake
Nov 25, 2025No plan
Daniel Woolson
VP, GM-Infusion Capital · sold 2,897 at $152.35
441K
20% of stake
Nov 11, 2025No plan
Virginia Ruth Sanzone
VP, General Counsel · sold 930 at $142.35
132K
15% of stake
Nov 11, 2025No plan
Elisha W Finney
Director · sold 1,285 at $140.42
180K
24% of stake
Aug 27, 2025
David C. Greenberg
Director · bought 1,200 at avg $126.41
152K
17% of stake
Aug 14, 2025
Vivek Jain
Chairman and CEO · bought 21,929 at avg $112.83
$2.47M
11% of stake
May 30, 2025No plan
Virginia Ruth Sanzone
VP, General Counsel · sold 700 at $133.62
94K
9.9% of stake
May 27, 2025 – May 28, 2025No plan
Christian B. Voigtlander
Chief Operating Officer · sold 9,930 at avg $129.74
$1.29M
62% of stake
May 22, 2025 – May 23, 2025No plan
Christian B. Voigtlander
Chief Operating Officer · sold 9,918 at avg $130.02
$1.29M
67% of stake
May 20, 2025 – May 21, 2025No plan
Christian B. Voigtlander
Chief Operating Officer · sold 9,788 at avg $135.05
$1.32M
73% of stake
May 19, 2025No plan
Elisha W Finney
Director · sold 600 at $138.92
83K
16% of stake
May 16, 2025 – May 19, 2025No plan
Christian B. Voigtlander
Chief Operating Officer · sold 11,110 at avg $139.00
$1.54M
82% of stake
May 15, 2025No plan
Ben Sousa
Chief Information Officer · sold 2,000 at $137.36
275K
81% of stake
May 14, 2025 – May 15, 2025No plan
Christian B. Voigtlander
Chief Operating Officer · sold 11,111 at avg $137.10
$1.52M
82% of stake
May 13, 2025No plan
David C. Greenberg
Director · sold 1,942 at $143.66
279K
21% of stake
Jan 2, 202510b5-1 plan
Vivek Jain
Chairman and CEO · sold 1,373 at $155.48
213K
0.7% of stake
Dec 6, 2024No plan
Daniel Woolson
VP, GM-Infusion Capital · sold 2,241 at $156.25
350K
17% of stake
Dec 2, 202410b5-1 plan
Vivek Jain
Chairman and CEO · sold 12,000 at avg $162.91
$1.95M
5.8% of stake
Nov 27, 2024No plan
Christian B. Voigtlander
Chief Operating Officer · sold 1,430 at $158.00
226K
100% of stake
Nov 27, 2024No plan
David C. Greenberg
Director · sold 972 at $158.11
154K
15% of stake
Nov 25, 2024 – Nov 26, 2024No plan
Christian B. Voigtlander
Chief Operating Officer · sold 9,681 at avg $161.14
$1.56M
100% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ICUI, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with ICUI

CompareIntrinsic value

TFXTeleflex Incorporated

$149.87+7.09%16

IARTIntegra LifeSciences Holdings Corporation

$14.82+8.73%28

MMSIMerit Medical Systems, Inc.

$90.63+7.69%61

PENPenumbra Inc.

$322.45+0.76%72

PODDInsulet Corporation

$165.02+6.56%75

HAEHaemonetics Corporation

$127.42+5.94%53

GMEDGlobus Medical Inc.

$87.10+9.45%71

MMEDMiniMed Group, Inc.

$19.29+2.33%25

Held by ETFs

ICUI is in 80 US ETFs. The largest of them, with ICUI's weight in each:

Spot a number that looks wrong? Check it in ICUI's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ICUI

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.